Accustem Sciences (ACUT) Capital Expenditures (2022)

Accustem Sciences (ACUT) posted quarterly Capital Expenditures of $2796.0 for Q2 2022, down 65.91% quarter-over-quarter from $8203.0 in Q1 2022.

Accustem Sciences (ACUT) Capital Expenditures (2022) Analysis & Trends

Accustem Sciences (ACUT) has reported Capital Expenditures for 1 consecutive years, with $2796.0 the latest figure, recorded in Q2 2022.

In Q2 2022, Capital Expenditures changed N/A year-over-year to $2796.0; the TTM figure through Dec 2022 stood at $10999.0 (changed N/A YoY), while the FY2022 annual figure was $10999.0, changed N/A from the prior year.
Capital Expenditures retreated to $2796.0 in Q2 2022 per ACUT's latest filing, from $8203.0 in the prior quarter.
Across five years, Capital Expenditures topped out at $8203.0 in Q1 2022 and bottomed at $2796.0 in Q2 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Capex (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	112.20 Mn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	240.20 Mn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	-
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	37.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	25.02 Mn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	34.68 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	-73.57 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	6.26 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	251.02 Mn
10	Accustem Sciences	2.57 Mn	2.56 Mn	-	-

Download Data